AI Threat Assessment · 27 May 2026

Trinity Life Sciences

Pharma Consulting
COOKED
6.7/ 10

“Trinity built exactly what Big Pharma wanted: a full-service commercialization consultancy with proprietary forecasting models, launch playbooks, and enough MBAs to staff a small country. They turned pharma's terror of botched launches into a $200M+ revenue engine, complete with TrinityEDGE™ platforms that promise 'AI-powered insights' and 'always-on intelligence.' The problem is that Claude now does strategic planning faster than their PowerPoint factories can format the slides, and ChatGPT writes more compelling market access strategies than their HEOR teams — without the six-figure retainer or the 12-week delivery timeline.”

Business Model
7.5
Automation Risk
7.0
Moat Strength
5.0
Adaptability
6.0
Need Survival
6.5
AI Threat Level
BUSINESS MODEL REPLACEABILITY

Trinity's value prop is 'we blend human expertise with AI to accelerate commercialization decisions' — which sounds forward-thinking until you realise Claude can now generate competitive intelligence reports, pricing strategies, and launch plans that pharma executives prefer to the ones Trinity charges $50K per slide deck to produce.

7.5
WORKFORCE AUTOMATION RISK

Market research analysts, commercial strategists, and HEOR consultants — the humans who turn raw pharma data into actionable insights — are watching Claude do their jobs with better citations, faster turnaround, and without the overhead of Trinity's 'integrated approach' that somehow always requires three more workstreams.

7.0
MOAT STRENGTH

The real moat isn't their AI platform or their 'proprietary methodologies' — it's that pharma executives would rather pay Trinity to be wrong than risk being wrong themselves with a free AI tool. Risk aversion is a genuine structural advantage in life sciences, but only until the board starts asking why consulting spend went up 40% while launch success rates stayed flat.

5.0
AI ADAPTABILITY SIGNALS

Their blog promises 'Digital Twins of HCPs' and 'always-on intelligence' while their actual AI strategy appears to be bolting GPT onto their existing workflows and calling it InsightsEDGE™ — the consulting equivalent of putting racing stripes on a minivan and calling it innovation.

6.0
WILL THE NEED SURVIVE AI?

Pharma commercialization expertise survives; paying Trinity $2M to tell you what Claude figured out in 20 minutes doesn't. The need shifts from 'hire consultants to think for us' to 'hire validators to check what AI already recommended' — a much smaller, much cheaper market.

6.5
Verdict

“Trinity spent two decades becoming the McKinsey of pharma launches, perfecting the art of charging premium rates for pattern recognition that AI now does for free. They're still booking new clients, but each contract is buying them less differentiation and more time to figure out what consulting looks like when the insights are commoditised and only the courage to act on them isn't.”

Scores are based on public information and AI analysis. This is an affectionate roast, not a financial assessment. The best companies use this as a mirror, not a verdict.

Roast another →